Claims for Patent: 11,813,266

Summary for Patent: 11,813,266

Title:	Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Abstract:	The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.
Inventor(s):	Franziska Elena HERRMANN, Peter Nickolaus, Stefan Ludwig Michael WOLLIN
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/811,914
Patent Claims:	1. A pharmaceutical composition comprising: a PDE4B-inhibitor of formula III wherein S* is a sulphur atom that represents a chiral center, Nintedanib in the form of its monoethanesulfonate, and optionally, one or more pharmaceutically acceptable carriers and/or excipients. 2. A kit comprising: a first pharmaceutical composition or dosage form comprising a PDE4B-inhibitor of formula III wherein S* is a sulphur atom that represents a chiral center, and optionally, one or more pharmaceutically acceptable carriers and/or excipients; and a second pharmaceutical composition or dosage form comprising Nintedanib in the form of its monoethanesulfonate and, optionally, one or more pharmaceutically acceptable carriers and/or excipients. 3. The kit according to claim 2, further comprising a package insert comprising printed instructions for simultaneous, concurrent, sequential, successive, alternate or separate use of the first and the second pharmaceutical composition or dosage forms in the treatment of one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). 4. The kit according to claim 2, further comprising a package insert comprising printed instructions for simultaneous, concurrent, sequential, successive, alternate or separate use of the first and the second pharmaceutical composition or dosage forms in the treatment of Idiopathic Pulmonary Fibrosis (IPF). 5. A method of treating one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), comprising administering to a patient in need thereof a therapeutically effective amount of a PDE4B-inhibitor of formula III wherein S* is a sulphur atom that represents a chiral center, and a therapeutically effective amount of Nintedanib in the form of its monoethanesulfonate. 6. The method of claim 5, wherein the Progessive Fibrosing Interstitial Lung Disease is Idiopathic Pulmonary Fibrosis (IPF). 7. The method according to claim 5, wherein the PDE4B-inhibitor of formula III is administered simultaneously, concurrently, sequentially, successively, alternately or separately with the Nintedanib in the form of its monoethanesulfonate.